Skip to content

Study · Animal study (in vivo) · mouse · 2024

10 results

Mitochondrial antioxidant elamipretide improves learning and memory impairment induced by chronic sleep deprivation in mice.

Zhang YM, Wang YT, Wei RM, Li XY, Luo BL, Zhang JY, Zhang KX, Fang SK, Liu XC, Chen GH

Brain and behavior1 May 2024Cited by 14 (Europe PMC)

PMID38688894 (opens in a new tab)PMCIDPMC11061203 (opens in a new tab)DOI10.1002/brb3.3508 (opens in a new tab)PepBankPUB-38688894
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

BackgroundThe inflammation and synaptic dysfunction induced by mitochondrial dysfunction play essential roles in the learning and memory impairment associated with sleep dysfunction. Elamipretide (SS-31), a novel mitochondrion-targeted antioxidant, was proven to improve mitochondrial dysfunction, the inflammatory response, synaptic dysfunction, and cognitive impairment in models of cerebral ischemia, sepsis, and type 2 diabetes. However, the potential for SS-31 to improve the cognitive impairment induced by chronic sleep deprivation (CSD) and its underlying mechanisms is unknown.MethodsAdult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg). The novel object recognition and Morris water maze test were used to evaluate hippocampus-dependent cognitive function. Western blotting and reverse transcription-quantitative polymerase chain reaction assays were used to determine the effects of CSD and SS-31 on markers of mitochondria, inflammation response, and synaptic function. Enzyme-linked immunosorbent assays were used to examine the levels of proinflammatory cytokines.ResultsSS-31 could improve the cognitive impairment induced by CSD. In particular, SS-31 treatment restored the CSD-induced decrease in sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator alpha levels and the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha. Furthermore, SS-31 significantly increased the levels of brain-derived neurotrophic factor, postsynaptic density protein-95, and synaptophysin in CSD mice.ConclusionTaken together, these results suggest that SS-31 could improve CSD-induced mitochondrial biogenesis dysfunction, inflammatory response, synaptic dysfunction, and cognitive impairment by increasing SIRT1 expression levels.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with chronic sleep deprivation, SS‑31 improved the cognitive impairment that the sleep deprivation caused.

    In plain wordsIn mice kept sleep-deprived, SS‑31 reduced the memory and learning problems caused by sleep loss.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCognitive impairment induced by chronic sleep deprivation
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 could improve the cognitive impairment induced by CSD.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 treatment restored the sleep-deprivation-induced decrease in SIRT1 levels.

    In plain wordsIn mice kept sleep-deprived, SS‑31 brought back the SIRT1 protein level that sleep loss had lowered.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSIRT1 level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    In particular, SS-31 treatment restored the CSD-induced decrease in sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator alpha levels and the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 treatment restored the sleep-deprivation-induced decrease in PGC-1 alpha levels.

    In plain wordsIn mice kept sleep-deprived, SS‑31 brought back the PGC-1 alpha level that sleep loss had lowered.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePGC-1 alpha level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    In particular, SS-31 treatment restored the CSD-induced decrease in sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator alpha levels and the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 treatment restored the sleep-deprivation-induced increase in nuclear factor kappa-B levels.

    In plain wordsIn mice kept sleep-deprived, SS‑31 lowered the NF-kB level that sleep loss had raised.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNF-kB level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    In particular, SS-31 treatment restored the CSD-induced decrease in sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator alpha levels and the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 treatment restored the sleep-deprivation-induced increase in IL-1beta.

    In plain wordsIn mice kept sleep-deprived, SS‑31 lowered the IL-1beta level that sleep loss had raised.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseIL-1beta level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    In particular, SS-31 treatment restored the CSD-induced decrease in sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator alpha levels and the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 treatment restored the sleep-deprivation-induced increase in IL-6.

    In plain wordsIn mice kept sleep-deprived, SS‑31 lowered the IL-6 level that sleep loss had raised.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseIL-6 level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    In particular, SS-31 treatment restored the CSD-induced decrease in sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator alpha levels and the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 treatment restored the sleep-deprivation-induced increase in tumor necrosis factor-alpha.

    In plain wordsIn mice kept sleep-deprived, SS‑31 lowered the TNF-alpha level that sleep loss had raised.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTNF-alpha level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    In particular, SS-31 treatment restored the CSD-induced decrease in sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator alpha levels and the increase in levels nuclear factor kappa-B and inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 significantly increased brain-derived neurotrophic factor levels.

    In plain wordsIn mice kept sleep-deprived, SS‑31 raised the level of BDNF, a protein that supports nerve cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseBDNF level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, SS-31 significantly increased the levels of brain-derived neurotrophic factor, postsynaptic density protein-95, and synaptophysin in CSD mice.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 significantly increased postsynaptic density protein-95 levels.

    In plain wordsIn mice kept sleep-deprived, SS‑31 raised the level of PSD-95, a protein found at nerve-cell connections.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePSD-95 level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, SS-31 significantly increased the levels of brain-derived neurotrophic factor, postsynaptic density protein-95, and synaptophysin in CSD mice.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice with chronic sleep deprivation, SS‑31 significantly increased synaptophysin levels.

    In plain wordsIn mice kept sleep-deprived, SS‑31 raised the level of synaptophysin, a protein found at nerve-cell connections.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSynaptophysin level
    Study

    mousen: not reported in source

    Chronic sleep deprivation (activity wheel, 21 days)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5 mg/kg · intraperitoneal · 21 daysAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, SS-31 significantly increased the levels of brain-derived neurotrophic factor, postsynaptic density protein-95, and synaptophysin in CSD mice.
    1 context sentence
    Summary · context
    Adult c57BL/6J mice were subjected to CSD for 21 days using an activity wheel accompanied by daily intraperitoneal injection of SS-31 (5 mg/kg).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.